Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

373
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
373
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

462
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
462
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

330
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
330
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

712
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
712
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

751
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
751
Pharmacovigilance01:19

Pharmacovigilance

1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of Pregnancy Adverse Drug Reactions in Pharmacovigilance Reporting Systems: A Novel Algorithm Developed in EudraVigilance.

Drug safety·2024
Same author

Lessons Learned on Observed-to-Expected Analysis Using Spontaneous Reports During Mass Vaccination.

Drug safety·2024
Same author

The Role of the European Medicines Agency in the Safety Monitoring of COVID-19 Vaccines and Future Directions in Enhancing Vaccine Safety Globally.

Drug safety·2024
Same author

Global Cancer Drug Development-A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting.

JCO global oncology·2023
Same author

Safety Monitoring of COVID-19 Vaccines: Perspective from the European Medicines Agency.

Clinical pharmacology and therapeutics·2022
Same author

Reliance is key to effective access and oversight of medical products in case of public health emergencies.

Expert review of clinical pharmacology·2022

Related Experiment Video

Updated: Mar 30, 2026

Whole-body PET/MRI of Pediatric Patients: The Details That Matter
10:02

Whole-body PET/MRI of Pediatric Patients: The Details That Matter

Published on: December 19, 2017

15.6K

Usage of unpublished paediatric data.

Agnès Saint-Raymond1, Benjamin Pelle1, Cosimo Zaccaria1

  • 1European Medicines Agency (EMA), London, UK.

Archives of Disease in Childhood
|November 7, 2015
PubMed
Summary

The European Paediatric Regulation enhances pediatric medicine information by reviewing studies. This initiative has led to new indications and improved data accessibility for researchers and healthcare professionals.

Keywords:
Evidence Based MedicineNeonatologyTherapeutics

More Related Videos

A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)
07:01

A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)

Published on: February 7, 2025

959
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.8K

Related Experiment Videos

Last Updated: Mar 30, 2026

Whole-body PET/MRI of Pediatric Patients: The Details That Matter
10:02

Whole-body PET/MRI of Pediatric Patients: The Details That Matter

Published on: December 19, 2017

15.6K
A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)
07:01

A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)

Published on: February 7, 2025

959
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.8K

Area of Science:

  • Pharmaceutical Science
  • Pediatric Medicine
  • Regulatory Affairs

Background:

  • The European Paediatric Regulation (EC No 1901/2006) aims to improve pediatric medicines through increased appropriate drug options, enhanced information, and ethical research.
  • Article 45 mandates pharmaceutical companies to submit existing pediatric study data for regulatory review and product information updates.

Purpose of the Study:

  • To assess the impact and outcomes of the European Paediatric Regulation on pediatric medicine development and information dissemination.
  • To evaluate the review process of submitted pediatric study reports and their contribution to updating product information.

Main Methods:

  • Identification and review of approximately 19,000 study reports for a thousand active substances.
  • Assessment of data by member states' competent authorities in collaboration with the European Medicines Agency (EMA).
  • Analysis of outcomes, including new pediatric indications and updates to product information.

Main Results:

  • Over 7 years, 262 active substances (including 62 centrally approved and nearly 200 nationally approved medicines) have been assessed.
  • The review has resulted in 16 new pediatric indications, addressing unmet needs, particularly in younger age groups.
  • Public accessibility of reviewed data through an EMA database and the European Clinical Trials Register.

Conclusions:

  • The European Paediatric Regulation is effectively increasing pediatric medicine information and addressing unmet needs.
  • Publicly accessible data enhances awareness for researchers and healthcare professionals, preventing redundant pediatric trials.
  • The regulation successfully stimulates high-quality ethical research with children and improves drug utilization in pediatric populations.